Erenumab PK, target binding, and receptor pharmacology
A subcutaneous quasi-steady-state TMDD model coupling erenumab disposition to CGRP-receptor abundance, unbound antibody, drug-target complex, and cumulative exposure.
- Therapeutic
- Erenumab
- Target
- CGRP receptor, CALCRL, RAMP1, calcitonin gene-related peptide receptor
- Disease
- Migraine prevention and CGRP-receptor pharmacology
Biological model
A subcutaneous quasi-steady-state TMDD model coupling erenumab disposition to CGRP-receptor abundance, unbound antibody, drug-target complex, and cumulative exposure.
Model details
A subcutaneous quasi-steady-state TMDD model coupling erenumab disposition to CGRP-receptor abundance, unbound antibody, drug-target complex, and cumulative exposure.
Modeled states
- AUC totalug*day/mL
Modeled dynamic state for auc total.
- A depotmg
Modeled dynamic state for a depot.
- A peripheralmg
Modeled dynamic state for a peripheral.
- A total centralmg
Modeled dynamic state for a total central.
- R totalng/mL
Modeled dynamic state for r total.
- elapsed timeday
Modeled dynamic state for elapsed time.
Key readouts
- Total erenumab concentrationunknown
Model-derived readout for total erenumab concentration.
- Unbound erenumab concentrationunknown
Model-derived readout for unbound erenumab concentration.
- Erenumab–receptor complexunknown
Model-derived readout for erenumab–receptor complex.
- Total CGRP receptorng/mL
Model-derived readout for total cgrp receptor.
- Cumulative total exposureunknown
Model-derived readout for cumulative total exposure.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
7 mg SC every 4 weeks 75 kg deterministic simulation
How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time? Explore this intervention regimen through Total erenumab concentration, Unbound erenumab concentration, Erenumab–receptor complex, Total CGRP receptor, Cumulative total exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time?
CL ref L day
Model parameter controlling cl ref l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine SubjectsPharmaceutical Research
